We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAdial Pharmaceuticals Inc

Adial Pharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2026-11-12T15:35:12.212140Z
Market Cap
2.27M

Momentum Score

…

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
1.54
Low
21.38
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Adial Pharmaceuticals Inc appears to be a small development-stage pharmaceutical company with limited publicly available disclosures. Long-term growth may depend on achievement of clinical or regulatory milestones, successful licensing or partnerships, and eventual commercialization of any approved therapies. Investors may find the company attractive because milestone-driven progress could create significant upside relative to its current market profile.

Key investment risks include high clinical and regulatory failure probability, persistent lack of revenue, ongoing capital needs that could cause dilution, and thin trading liquidity.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
4.05
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.06
ROE
-170.73%
Net Debt
-5.88M
ROCE
-147.83%
Diluted EPS TTM
-11.93

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -7.98M -13.20M -7.00M -12.73M -19.52M
Net income -7.98M -13.20M -7.00M -12.73M -19.42M
Selling general administrative 5.18M 5.06M 5.62M 9.14M 9.34M
Selling and marketing expenses - - 0.00M - -
Gross profit -0.00M -0.00M -0.00M - -
Reconciled depreciation 0.00M 0.00M 0.06M 0.06M 0.06M
Ebit -7.80M -8.28M -7.00M -13.32M -19.29M
Ebitda -7.80M -8.28M -7.00M -13.78M -15.86M
Depreciation and amortization 0.00M 0.00M 0.00M -0.46M 3.43M
Operating income -7.80M -8.28M -6.89M -13.32M -19.29M
Other operating expenses 7.80M 8.28M 6.89M 13.32M 17.74M
Interest expense - - - 0.59M 3.61M
Tax provision - 0.00M -0.00M -0.00M -0.09M
Interest income 0.15M 0.18M 0.11M 0.06M 0.01M
Net interest income 0.15M 0.18M 0.11M 0.06M 0.01M
Income tax expense - - -1.88M -0.00M -0.09M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 7.80M 8.28M 6.89M 13.32M 17.74M
Cost of revenue 0.00M 0.00M 0.00M - -
Total other income expense net -0.18M -4.91M -0.11M 0.59M -0.23M
Net income from continuing ops -7.98M -13.20M -9.58M -12.73M -19.42M
Net income applicable to common shares - - - - -19.42M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 6.67M 5.04M 4.74M 5.73M 7.47M
Intangible assets 0.00M 0.00M 0.00M 0.46M 0.46M
Other current assets 0.26M 0.31M 0.37M 0.35M 0.39M
Total liab 1.40M 0.98M 0.65M 2.46M 3.97M
Total stockholder equity 5.28M 4.07M 4.08M 3.28M 3.51M
Other current liab 0.74M 0.73M 0.53M 1.34M 0.01M
Common stock 0.00M 0.01M 0.00M 0.03M 0.02M
Capital stock 0.00M 0.01M - 0.03M 0.02M
Retained earnings -89.97M -82.00M -68.80M -63.67M -50.94M
Other liab - - - - 1.04M
Good will - - - 0.25M 0.25M
Cash 5.88M 3.75M 2.83M 4.00M 6.06M
Total current liabilities 1.40M 0.98M 0.65M 1.79M 2.72M
Current deferred revenue - - - - 2.38M
Net debt -5.88M -3.75M -2.83M -3.79M -5.81M
Short term debt - - - 0.06M 0.05M
Short long term debt total - - - 0.21M 0.26M
Other stockholder equity 95.25M 86.06M 72.88M 66.92M 54.43M
Property plant equipment - - - - 0.30M
Total current assets 6.18M 4.06M 3.20M 4.78M 6.46M
Long term investments 0.49M 0.98M - - -
Net tangible assets - - - - 2.80M
Net receivables 0.04M - - - -
Accounts payable 0.66M 0.25M 0.13M 0.39M 0.29M
Non currrent assets other 0.49M - 1.53M 0.65M 0.70M
Non current assets total 0.49M 0.99M 1.54M 0.95M 1.01M
Capital lease obligations - - - 0.21M 0.26M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M 1.15M 0.00M -0.03M
Change to liabilities - - - - -0.35M
Total cashflows from investing activities 0.15M - 1.50M - -0.03M
Total cash from financing activities 8.47M 7.85M 4.13M 9.13M 13.64M
Change to operating activities - - - - 1.46M
Net income -7.98M -13.20M -7.00M -12.73M -19.42M
Change in cash 2.13M 0.92M -1.17M -2.06M 1.66M
Begin period cash flow 3.75M 2.83M 4.00M 6.06M 4.40M
End period cash flow 5.88M 3.75M 2.83M 4.00M 6.06M
Total cash from operating activities -6.49M -6.92M -6.81M -11.19M -11.95M
Issuance of capital stock 3.66M 4.02M 0.75M 9.12M 11.75M
Depreciation 0.00M 0.00M 0.00M 0.06M 0.06M
Other cashflows from investing activities 0.15M - 1.50M - -
Sale purchase of stock - - -0.00M - -
Other cashflows from financing activities 8.47M 3.82M 4.13M 0.00M 1.89M
Change to netincome - - - - 5.95M
Capital expenditures 0.00M 0.00M 6.81M 0.00M 0.06M
Change in working capital 0.47M 0.39M -0.79M -1.37M 1.46M
Stock based compensation 0.68M 0.80M 1.75M 3.37M 4.24M
Other non cash items 0.34M 5.09M -0.76M -0.52M 1.81M
Free cash flow -6.49M -6.92M -6.81M -11.19M -12.01M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Adial Pharmaceuticals Inc

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.

4870 Sadler Road, Glen Allen, VA, United States, 23060

804 487 8196

https://www.adial.com

5

Name Title Year Born
Mr. Cary John Claiborne MBA CEO, Pres & Director 1961
Mr. Joseph A. M. Truluck M.B.A., MBA CFO, Treasurer & Sec. 1978
Dr. Bankole A. Johnson DSc, FRCPsych, M.D., M.Phil, Ph.D. Founder & Chief Medical Officer 1960
Mr. John R. Martin J.D. Gen. Counsel NA
Mr. Alex Lugovoy Chief Bus. Officer NA
Dr. Jack W. Reich Ph.D. Head of Regulatory 1949
Mr. Mark H. Peikin Chief Strategy Officer & Chief Devel. Officer NA
Mr. Lawrence Goldman CPA Controller 1956
Ms. Catherine Fratila Controller NA
Mr. Cary John Claiborne MBA CEO, President & Director 1961

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…